- Home
- ACIC vs PLRX Comparison
ACIC vs PLRX Comparison
Compare ACIC & PLRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
N/A
N/A
Current Price
$1.39
Company Overview
Basic Information| Metric | ACIC | PLRX |
|---|---|---|
| Founded | 1999 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Property-Casualty Insurers | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 625.2M | 79.9M |
| IPO Year | 2007 | 2020 |
Fundamental Metrics
Financial Performance| Metric | ACIC | PLRX |
|---|---|---|
| Price | $11.30 | $1.39 |
| Analyst Decision | Hold | Hold |
| Analyst Count | 1 | 4 |
| Target Price | N/A | ★ $3.00 |
| AVG Volume (30 Days) | 315.9K | ★ 568.7K |
| Earning Date | 05-21-2026 | 06-08-2026 |
| Dividend Yield | ★ 6.73% | N/A |
| EPS Growth | ★ 39.61 | 29.97 |
| EPS | ★ 2.15 | N/A |
| Revenue | ★ $335,439,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $3.14 | N/A |
| P/E Ratio | $5.18 | ★ N/A |
| Revenue Growth | ★ 13.07 | N/A |
| 52 Week Low | $9.97 | $1.09 |
| 52 Week High | $13.06 | $1.95 |
Technical Indicators
Market Signals| Indicator | ACIC | PLRX |
|---|---|---|
| Relative Strength Index (RSI) | 49.29 | 64.94 |
| Support Level | $10.96 | $1.12 |
| Resistance Level | $11.85 | $1.43 |
| Average True Range (ATR) | 0.36 | 0.06 |
| MACD | 0.01 | 0.01 |
| Stochastic Oscillator | 66.25 | 91.89 |
Price Performance
Historical Comparison ACIC
PLRX
About ACIC American Coastal Insurance Corporation
American Coastal Insurance Corp is a holding company that underwrites commercial residential property and casualty insurance policies in the United States through its wholly-owned insurance subsidiary.
About PLRX Pliant Therapeutics Inc.
Pliant Therapeutics Inc is a clinical-stage biopharmaceutical company focused on discovering and developing novel therapies for the treatment of fibrosis and related diseases. Its primary product candidate is bexotegrast (PLN-74809), an oral, small molecule, that the company is developing for the treatment of idiopathic pulmonary fibrosis, or IPF, and primary sclerosing cholangitis.